The Administrative Core of the Yale SPORE in Skin Cancer (YSPORE) consists of the PI, Ruth Halaban, and the two Co-PIs Mario Sznol and Robert Tigelaar. The main responsibilities of the three directors are to lead the program, set basic and translational research priorities, identify new translational research opportunities from cutting-edge scientific progress, engage new investigators in skin cancer research, address critical issues, monitor progress, oversee the performance of the Cores and Projects, promote communication and collaboration among scientists in Yale and other SPOREs, introduce changes in YSPORE's projects and direction of translational research as required, and participate in recruiting new investigators in the field of skin cancer to the Yale Cancer Center/Yale School of Medicine. Major decisions are reached after discussions with the Executive Committee, composed of several leaders of projects and cores, and the Internal and External Boards of Advisors. The directors handle the day-to-day administration of the YSPORE. They work as a team to ensure efficient information transfer between Investigators, cost-effective operation of the projects, and sharing of resources to avoid duplication, proper deployment of core facility resources, comprehensive data management and archiving, and maintenance of the infrastructure required for all YSPORE-related studies. The directors also seek new funding from donors or other venues that facilitate the expansion of the YSPORE translational research. They manage and distribute new funding, foster novel pilot projects and clinical trials, ensure balanced representation of ethnic-racial/gender populations, and provide oversight and management of the financial and administrative aspects of the YSPORE. The Administrative Core serves as the liaison with the leadership of the Yale Comprehensive Cancer Center, coordinates YCCC activities with Skin Cancer SPORE activities, organizes meetings, schedules invited speakers, and encourages the participation of YSPORE scientists in national SPORE workshops.

Agency
National Institute of Health (NIH)
Type
Specialized Center (P50)
Project #
5P50CA121974-08
Application #
8719046
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06510
Brash, Douglas E (2015) UV signature mutations. Photochem Photobiol 91:15-26
Jilaveanu, Lucia B; Parisi, Fabio; Barr, Meaghan L et al. (2015) PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clin Cancer Res 21:2138-47
Kong, Yong; Krauthammer, Michael; Halaban, Ruth (2014) Rare SF3B1 R625 mutations in cutaneous melanoma. Melanoma Res 24:332-4
Taube, Janis M; Klein, Alison; Brahmer, Julie R et al. (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064-74
Zito, Giovanni; Saotome, Ichiko; Liu, Zongzhi et al. (2014) Spontaneous tumour regression in keratoacanthomas is driven by Wnt/retinoic acid signalling cross-talk. Nat Commun 5:3543
Leonhardt, Ralf M; Abrahimi, Parwiz; Mitchell, Susan M et al. (2014) Three tapasin docking sites in TAP cooperate to facilitate transporter stabilization and heterodimerization. J Immunol 192:2480-94
Sanmamed, Miguel F; Chen, Lieping (2014) Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 20:256-61
Ho, Ping-Chih; Meeth, Katrina M; Tsui, Yao-Chen et al. (2014) Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFN?. Cancer Res 74:3205-17
Paglino, Justin C; Andres, Wells; van den Pol, Anthony N (2014) Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells. J Virol 88:4932-42
Troche, Jose Ramon; Ferrucci, Leah M; Cartmel, Brenda et al. (2014) Systemic glucocorticoid use and early-onset basal cell carcinoma. Ann Epidemiol 24:625-7

Showing the most recent 10 out of 86 publications